Evidence map›Paper›PMID 29290996›Full record

ArticleOncotarget2017

The role of talin2 in breast cancer tumorigenesis and metastasis.

Liqing Li, Xiang Li, Lei Qi, Piotr Rychahou, Naser Jafari, Cai Huang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. [Expression of miR-4324 and its targeted gene Talin2 in breast cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Liqing LiMarkey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
Xiang LiMarkey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
Lei QiMarkey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
Piotr RychahouMarkey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
Naser JafariMarkey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
Cai HuangMarkey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
University of Kentucky · USMarkey Cancer Center · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Novel pRNA Nanoparticle Delivery as Directed Therapy for Colorectal Cancer MetastasisR01CA195573 · NCI · UNIVERSITY OF KENTUCKY · PI EVERS, BERNARD MARK, GUO, PEIXUAN · 2015 to 2019
$1.8M
Talin2-mediated traction force drives MMP secretion and cell invasionR01GM122994 · NIGMS · UNIVERSITY OF KENTUCKY · PI HUANG, CAI · 2017 to 2017
$300k
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA195573NIGMS NIH HHS R01 GM122994
6 · The paper itself

Abstract

Recent studies show that talin2 has a higher affinity to β-integrin tails and is indispensable for traction force generation and cell invasion. However, its roles in cell migration, cancer cell metastasis and tumorigenesis remain to be determined. Here, we used MDA-MB-231 human breast cancer cells as a model to define the roles of talin2 in cell migration, invasion, metastasis and tumorigenesis. We show here that talin2 knockdown (KD) inhibited cell migration and focal adhesion dynamics, a key step in cell migration, and that talin2 knockout (KO) inhibited cell invasion and traction force generation, the latter is crucial for cell invasion. Re-expression of talin2

Indexed as

cell migrationinvasionmetastasistalin2tumor growth

Identifiers

PMID29290996
PMCPMC5739781
OpenAlexW2769620181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.